3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hematologic Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Rituximab
301
Cyclophosphamide
241
Peripheral Blood Stem Cell Transplantation
115
fludarabine phosphate
111
Filgrastim
93
Etoposide
85
Radiotherapy
81
Lenalidomide
81
Vincristine
79
Prednisone
79
Mycophenolic Acid
67
Doxorubicin
62
Whole-Body Irradiation
59
Cyclosporine
59
Bendamustine Hydrochloride
59
Melphalan
57
Tacrolimus
54
Busulfan
52
obinutuzumab
50
fludarabine
50
Cytarabine
49
Methotrexate
45
Antilymphocyte Serum
43
Bortezomib
42
Methylprednisolone
37
Carmustine
37
sargramostim
36
ibritumomab tiuxetan
33
ibrutinib
30
Dexamethasone
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
pasireotide
×
Lymphoid
×
Clear all
NCT06784752
2026-04-30
NETTER-3
Novartis
Phase 3
Recruiting
240 enrolled